№ files_lp_3_process_9_33457
File format: docx
Character count: 4860
File size: 33 KB
Year:
2023
Region / City:
Global
Topic:
Research
Document Type:
Technical Data Sheet
Organization / Institution:
Abcam
Author:
Abcam
Target Audience:
Researchers, Laboratory Technicians
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Description:
Technical data sheet detailing the usage and protocol for the COX2 Inhibitor Screening Kit (Fluorometric), a product intended for high-throughput screening of COX-2 inhibitors in research laboratories.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / City:
Zhejiang Province, China
Topic:
Epilepsy, Neuroscience
Document Type:
Research Article
Organization / Institution:
Zhejiang University
Author:
Lin Zhou, Liang Zhou, Li-Da Su, Sheng-Long Cao, Ya-Jun Xie, Ying Shen
Target Audience:
Researchers in neuroscience and epilepsy
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2019
Region / City:
Australia
Topic:
Pharmaceutical Benefits Scheme, PD-(L)1 inhibitors, non-small cell lung cancer (NSCLC)
Document type:
Meeting minutes
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Professor Andrew Wilson (PBAC Chair)
Target audience:
Stakeholders in the healthcare and pharmaceutical industry
Period of validity:
2019 and onwards
Date of approval:
February 2019
Date of amendments:
Not specified
Year:
2021
Region / city:
N/A
Document type:
Research supplementary materials
Organization / institution:
University of North Carolina
Author:
Ling Xie, Ryan N. Sheehy, Yan Xiong, Adil Muneer, John A. Wrobel, Kwang-Su Park, Julia Velez, Jing Liu, Yan-Jia Luo, Ya-Dong Li, Luis Quintanilla, Yongyi Li, Chongchong Xu, Mohanish Deshmukh, Zhexing Wen, Jian Jin, Juan Song, Xian Chen
Target audience:
Researchers in neuroscience, pharmacology, and precision medicine
Period of validity:
N/A
Approval date:
N/A
Date of amendments:
N/A
Year:
2013
Region / City:
Leeds, Yorkshire and The Humber
Theme:
Clinical trials, Chronic Kidney Disease
Document type:
Research study protocol
Organization:
University of Birmingham Clinical Trials Unit, Hull and East Yorkshire Hospitals NHS Trust
Author:
Prof Sunil Bhandari
Target audience:
Healthcare professionals, nephrologists, researchers
Period of validity:
3 years
Approval date:
2013
Change date:
N/A
Study reference number:
11/30/07
Ethics committee reference:
13/YH/0394
EudraCT number:
2013-003798-82
Sponsor:
Hull and East Yorkshire Hospitals NHS Trust
Funding source:
Efficacy and Mechanism Evaluation (EME) programme, National Institute for Health Research (NIHR), Medical Research Council (MRC)
Note:
Contextual description
Year:
2026
Region / City:
Global
Topic:
Pharmacogenetics, Antidepressants
Document Type:
Guideline
Organization / Institution:
Clinical Pharmacogenetics Implementation Consortium (CPIC)
Authors:
Chad A. Bousman, James M. Stevenson, Laura B. Ramsey, Katrin Sangkuhl, J. Kevin Hicks, Jeffrey R. Strawn, Ajeet B. Singh, Gualberto Ruaño, Daniel J. Mueller, Evangelia Eirini Tsermpini, Jacob T. Brown, Gillian C. Bell, J. Steven Leeder, Andrea Gaedigk, Stuart A. Scott, Teri E. Klein, Kelly E. Caudle, Jeffrey R. Bishop
Target Audience:
Healthcare professionals, geneticists, pharmacologists
Effective Period:
Ongoing
Approval Date:
2026
Modification Date:
Not specified
Year:
2026
Region / City:
Southampton, U.K.; Newcastle upon Tyne, U.K.; Cambridge, U.K.
Subject:
Biochemistry, Cancer Research
Document Type:
Research Article
Organization / Institution:
University of Southampton, Newcastle University, AstraZeneca
Author:
Eliot L. Osher, Francisco Castillo, Nagarajan Elumalai, Michael J. Waring, Garry Pairaudeau, Ali Tavassoli
Target Audience:
Researchers, Scientists, Medical Professionals
Duration:
Ongoing
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / city:
Benha, Al-Ahsa, Sohag, Alqurayat
Subject:
Corrosion inhibition, Surfactants, Electrochemical Analysis
Document Type:
Research Paper
Organization / Institution:
Benha University, King Faisal University, Sohag University, Jouf University
Author:
Mohamed A. Abo-Riya, Kamal A. Soliman, Hany M. Abd El-Lateef, Ahmed H. Tantawy, Salah Eid
Target Audience:
Researchers, Academics, Engineers in Materials Science and Chemistry
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Context:
A research paper examining the synthesis, properties, and performance of imine surfactants as corrosion inhibitors for carbon steel in acidic solutions.
Year:
2023
Region / City:
Ann Arbor, MI, USA
Topic:
Cancer Research, Glycolytic Metabolism, Cell Migration
Document Type:
Research Article
Organization:
University of Michigan
Authors:
Brock Humphries, Johanna M. Buschhaus, Yu-Chih Chen, Henry R. Haley, Tonela Qyli, Benjamin Chiang, Nathan Shen, Shrila Rajendran, Alyssa Cutter, Yu-Heng Cheng, Yu-Ting Chen, Jason Cong, Phillip C. Spinosa, Euisik Yoon, Kathryn E. Luker, Gary D. Luker
Target Audience:
Researchers, Medical Professionals, Oncology Specialists
Period of Action:
N/A
Date of Approval:
N/A
Date of Revisions:
N/A
Country:
United Kingdom
Topic:
Hereditary angioedema and acquired C1 inhibitor deficiency
Document type:
Medical research article
Study type:
National survey
Authors:
Patrick FK Yong; Tanya Coulter; Tariq El-Shanwany; Tomaz Garcez; Scott Hackett; Rashmi Jain; Sorena Kiani-Alikhan; Ania Manson; Sadia Noorani; Catherine Stroud; Christine Symons; Ravishankar Sargur; Cathal Steele; Hana Alachkar; Ariharan Anantharachagan; Peter D Arkwright; Jolanta Bernatoniene; Malini Bhole; Lindsay Brown; Matthew Buckland; Siobhan Burns; Charu Chopra; James Darroch; Elizabeth Drewe; Jillian Edmonds; Anjali Ekbote; Shuayb Elkhalifa; Sarah Goddard; Dorothea Grosse-Kreul; Padmalal Gurugama; Rosie Hague; Richard Herriot; Archana Herwadkar; Stephen M Hughes; Laura Jones; Sara Lear; Elizabeth McDermott; Sai Hurng Kham Murng; Arthur Price; Vyanka Redenbaugh; Alex Richter; Andrew Riordan; Fiona Shackley; Julia Stichbury; Debbie Springett; Michael D Tarzi; Moira Thomas; Pavaladurai Vijayadurai; Austen Worth
Institutions:
Multiple NHS trusts and university hospitals across England, Scotland, Wales, and Northern Ireland
Corresponding author:
Patrick FK Yong
Corresponding institution:
Frimley Health NHS Foundation Trust
Methodology:
Questionnaire survey of specialist centres managing hereditary angioedema and acquired C1 inhibitor deficiency
Number of participating centres:
37
Patient population:
Individuals with HAE-1/2, HAE with normal C1 inhibitor, and acquired C1 inhibitor deficiency
Sample size:
1265 patients
Medical conditions studied:
Hereditary angioedema; acquired C1 inhibitor deficiency
Key treatments mentioned:
Danazol; C1 inhibitor replacement therapy; icatibant; tranexamic acid
Funding source:
Unrestricted grant from Pharming
Keywords:
hereditary angioedema; acquired C1 inhibitor deficiency; epidemiology; demographics; treatment modalities; United Kingdom
Year:
2026
Research Institution:
[Not specified in document]
Cell Lines:
PEO1, TOV21G, UWB1.289
Genes Studied:
BRCA1, BRCA2, FZD10, ALKBH5, FTO, METTLE3, METTLE14, YTHDF2, HuR, IGF2BP2
Drugs:
Olaparib, Niraparib, Rucaparib, XAV939
Experimental Methods:
Immunoblotting, qRT-PCR, RNA electrophoresis, shRNA knockdown, lentiviral infection, HR and NHEJ reporter assays, apoptosis assays, mouse xenograft models
Target Pathways:
Wnt signaling, DNA repair pathways (HR and NHEJ)
Data Analysis Tools:
NIH ImageJ, statistical analysis via two-tailed t-test
Supplement Type:
Figure legends for supplementary data in molecular biology research
End Date of Experimentation:
Not specified
Year:
2018
Region:
Australia
Subject:
PD-1 and PD-L1 checkpoint inhibitor immunotherapies
Document Type:
Submission Template
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Intended Audience:
Patients, healthcare providers, researchers, pharmaceutical industry, government bodies
Submission Deadline:
29 June 2018
Contact Information Required:
Yes
Confidentiality Note:
Commercial-in-confidence or personal information to be redacted before publication
Format:
Electronic submission in Microsoft Word or text-based format
Questions Covered:
Advantages, disadvantages, unmet clinical need, evidence requirements, cost-effectiveness, subsidy pricing, biomarker considerations, extrapolation across medicines and cancer types, rare cancers, follow-up actions, clinical trials, international models
Year:
Not specified
Field:
Molecular Biology; Cancer Research
Disease Focus:
Prostate Cancer
Experimental Models:
VCaP cells; LNCaP cells; LNCaP-AR cells; Patient-Derived Xenograft (PDX) models
Key Compounds:
Enzalutamide; JQ1; OTX-015; I-BET762; DMSO
Experimental Methods:
Xenograft mouse experiments; RT-qPCR; ChIP-seq; Western blot; Cell viability assay
Measured Genes / Proteins:
AR; AR-V7; MYC; GR; SLC45A3; BRD2; BRD3; BRD4; SRSF1; U2AF1; ERG; H3K27ac; Med1
Statistical Methods:
Two-tailed Student’s t-test
Treatment Regimen:
30 mg/kg enzalutamide, 5 days per week for 5 weeks in xenografted mice
Sample Size:
Vehicle-treated mice (n=20); Enzalutamide-treated mice (n=20); Four wells per condition in cell viability assays
Source Type:
Supplementary material to a scientific research publication
Year:
2020
Region / City:
Shanghai, China
Subject:
Medical Case Report
Document Type:
Case Report
Organization / Institution:
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Author:
Ben Li, Guan-Wu Li, Luan Xue, Yue-Ying Chen
Target Audience:
Medical Professionals, Rheumatologists
Period of Action:
2020
Date of Approval:
August 29, 2020
Date of Revision:
June 18, 2020
Date of Publication:
October 06, 2020
Keywords:
Synovitis, acne, pustulosis, hyperostosis, osteitis syndrome, JAK inhibitor, tofacitinib, case report, rheumatoid arthritis, psoriatic arthritis
DOI:
https://dx.doi.org/10.12998/wjcc.v8.i19.4527
URL:
https://www.wjgnet.com/2307-8960/full/v8/i19/4527.htm
Context:
A medical case report describing the rapid response of a patient with SAPHO syndrome to the Janus kinase inhibitor tofacitinib after failure of conventional treatments.